Insider Transactions in Q4 2020 at Boston Scientific Corp (BSX)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2020
|
Jeffrey B. Mirviss EVP&Pres, Periph Intervent |
SELL
Bona fide gift
|
Direct |
150
-0.11%
|
-
|
|
Dec 11
2020
|
Jeffrey B. Mirviss EVP&Pres, Periph Intervent |
SELL
Bona fide gift
|
Direct |
50
-0.04%
|
-
|
|
Dec 03
2020
|
Jeffrey B. Mirviss EVP&Pres, Periph Intervent |
SELL
Payment of exercise price or tax liability
|
Direct |
296
-0.22%
|
$9,768
$33.81 P/Share
|
|
Dec 03
2020
|
Jeffrey B. Mirviss EVP&Pres, Periph Intervent |
BUY
Exercise of conversion of derivative security
|
Direct |
649
+0.49%
|
-
|
|
Dec 01
2020
|
Jeffrey B. Mirviss EVP&Pres, Periph Intervent |
SELL
Open market or private sale
|
Direct |
46,584
-26.16%
|
$1,537,272
$33.53 P/Share
|
|
Dec 01
2020
|
Jeffrey B. Mirviss EVP&Pres, Periph Intervent |
BUY
Exercise of conversion of derivative security
|
Direct |
46,584
+20.74%
|
$326,088
$7.16 P/Share
|
|
Dec 01
2020
|
Desiree Ralls Morrison SVP, GC and Corp Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
3,383
-14.76%
|
$111,639
$33.65 P/Share
|
|
Dec 01
2020
|
Desiree Ralls Morrison SVP, GC and Corp Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
11,472
+33.35%
|
-
|
|
Dec 01
2020
|
Scott Olson SVP & Pres, CRM, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
733
-5.81%
|
$24,189
$33.65 P/Share
|
|
Dec 01
2020
|
Scott Olson SVP & Pres, CRM, Diagnostics |
BUY
Exercise of conversion of derivative security
|
Direct |
1,485
+10.53%
|
-
|
|
Nov 09
2020
|
David A Pierce EVP Pres MedSurg |
SELL
Open market or private sale
|
Direct |
2,028
-75.39%
|
$79,092
$39.0 P/Share
|
|
Nov 03
2020
|
Michael F Mahoney Chairman, President & CEO |
SELL
Open market or private sale
|
Direct |
259,207
-11.68%
|
$9,072,245
$35.06 P/Share
|
|
Oct 01
2020
|
David A Pierce EVP Pres MedSurg |
SELL
Open market or private sale
|
Direct |
2,282
-45.9%
|
$86,716
$38.56 P/Share
|
|
Oct 01
2020
|
Stephen P Macmillan Director |
BUY
Grant, award, or other acquisition
|
Direct |
498
+5.86%
|
-
|